BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 25827822)

  • 1. Identification of a novel selective agonist of PPARγ with no promotion of adipogenesis and less inhibition of osteoblastogenesis.
    Liu C; Feng T; Zhu N; Liu P; Han X; Chen M; Wang X; Li N; Li Y; Xu Y; Si S
    Sci Rep; 2015 Apr; 5():9530. PubMed ID: 25827822
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel non-agonist peroxisome proliferator-activated receptor γ (PPARγ) ligand UHC1 blocks PPARγ phosphorylation by cyclin-dependent kinase 5 (CDK5) and improves insulin sensitivity.
    Choi SS; Kim ES; Koh M; Lee SJ; Lim D; Yang YR; Jang HJ; Seo KA; Min SH; Lee IH; Park SB; Suh PG; Choi JH
    J Biol Chem; 2014 Sep; 289(38):26618-26629. PubMed ID: 25100724
    [TBL] [Abstract][Full Text] [Related]  

  • 3. T2384, a novel antidiabetic agent with unique peroxisome proliferator-activated receptor gamma binding properties.
    Li Y; Wang Z; Furukawa N; Escaron P; Weiszmann J; Lee G; Lindstrom M; Liu J; Liu X; Xu H; Plotnikova O; Prasad V; Walker N; Learned RM; Chen JL
    J Biol Chem; 2008 Apr; 283(14):9168-76. PubMed ID: 18263587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chebulagic acid from Terminalia chebula enhances insulin mediated glucose uptake in 3T3-L1 adipocytes via PPARγ signaling pathway.
    Shyni GL; Kavitha S; Indu S; Arya AD; Anusree SS; Vineetha VP; Vandana S; Sundaresan A; Raghu KG
    Biofactors; 2014; 40(6):646-57. PubMed ID: 25529897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. L312, a novel PPARγ ligand with potent anti-diabetic activity by selective regulation.
    Xie X; Zhou X; Chen W; Long L; Li W; Yang X; Li S; Wang L
    Biochim Biophys Acta; 2015 Jan; 1850(1):62-72. PubMed ID: 25305559
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of a novel selective PPARγ ligand with a unique binding mode and improved therapeutic profile in vitro.
    Yi W; Shi J; Zhao G; Zhou XE; Suino-Powell K; Melcher K; Xu HE
    Sci Rep; 2017 Jan; 7():41487. PubMed ID: 28128331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological repression of PPARγ promotes osteogenesis.
    Marciano DP; Kuruvilla DS; Boregowda SV; Asteian A; Hughes TS; Garcia-Ordonez R; Corzo CA; Khan TM; Novick SJ; Park H; Kojetin DJ; Phinney DG; Bruning JB; Kamenecka TM; Griffin PR
    Nat Commun; 2015 Jun; 6():7443. PubMed ID: 26068133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhancing insulin sensitivity by dual PPARγ partial agonist, β-catenin inhibitor: Design, synthesis of new αphthalimido-o-toluoyl2-aminothiazole hybrids.
    Mourad AAE; Mourad MAE
    Life Sci; 2020 Oct; 259():118270. PubMed ID: 32814067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PPARγ partial agonist GQ-16 strongly represses a subset of genes in 3T3-L1 adipocytes.
    Milton FA; Cvoro A; Amato AA; Sieglaff DH; Filgueira CS; Arumanayagam AS; de Lima Mdo C; Pitta IR; de Assis Rocha Neves F; Webb P
    Biochem Biophys Res Commun; 2015 Aug; 464(3):718-23. PubMed ID: 26168725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of DSP-8658, a novel selective peroxisome proliferator-activated receptors a/γ modulator, on adipogenesis and glucose metabolism in diabetic obese mice.
    Goto T; Nakayama R; Yamanaka M; Takata M; Takazawa T; Watanabe K; Maruta K; Nagata R; Nagamine J; Tsuchida A; Kato H
    Exp Clin Endocrinol Diabetes; 2015 Sep; 123(8):492-9. PubMed ID: 26011171
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective targeting of PPARγ by the natural product chelerythrine with a unique binding mode and improved antidiabetic potency.
    Zheng W; Qiu L; Wang R; Feng X; Han Y; Zhu Y; Chen D; Liu Y; Jin L; Li Y
    Sci Rep; 2015 Jul; 5():12222. PubMed ID: 26183621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PPARγ agonists induce adipocyte differentiation by modulating the expression of Lipin-1, which acts as a PPARγ phosphatase.
    Kim J; Lee YJ; Kim JM; Lee SY; Bae MA; Ahn JH; Han DC; Kwon BM
    Int J Biochem Cell Biol; 2016 Dec; 81(Pt A):57-66. PubMed ID: 27780754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel specific peroxisome proliferator-activated receptor γ (PPARγ) modulator YR4-42 ameliorates hyperglycaemia and dyslipidaemia and hepatic steatosis in diet-induced obese mice.
    Huan Y; Pan X; Peng J; Jia C; Sun S; Bai G; Wang X; Zhou T; Li R; Liu S; Li C; Liu Q; Liu Z; Shen Z
    Diabetes Obes Metab; 2019 Nov; 21(11):2553-2563. PubMed ID: 31364797
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of a novel selective PPARγ ligand with partial agonist binding properties by integrated in silico/in vitro work flow.
    Kouskoumvekaki I; Petersen RK; Fratev F; Taboureau O; Nielsen TE; Oprea TI; Sonne SB; Flindt EN; Jónsdóttir SÓ; Kristiansen K
    J Chem Inf Model; 2013 Apr; 53(4):923-37. PubMed ID: 23432662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. N-Acetylfarnesylcysteine is a novel class of peroxisome proliferator-activated receptor γ ligand with partial and full agonist activity in vitro and in vivo.
    Bhalla K; Hwang BJ; Choi JH; Dewi R; Ou L; Mclenithan J; Twaddel W; Pozharski E; Stock J; Girnun GD
    J Biol Chem; 2011 Dec; 286(48):41626-41635. PubMed ID: 21979952
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antidiabetic actions of a non-agonist PPARγ ligand blocking Cdk5-mediated phosphorylation.
    Choi JH; Banks AS; Kamenecka TM; Busby SA; Chalmers MJ; Kumar N; Kuruvilla DS; Shin Y; He Y; Bruning JB; Marciano DP; Cameron MD; Laznik D; Jurczak MJ; Schürer SC; Vidović D; Shulman GI; Spiegelman BM; Griffin PR
    Nature; 2011 Sep; 477(7365):477-81. PubMed ID: 21892191
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The potential insulin sensitizing and glucose lowering effects of a novel indole derivative in vitro and in vivo.
    Li YY; Wu HS; Tang L; Feng CR; Yu JH; Li Y; Yang YS; Yang B; He QJ
    Pharmacol Res; 2007 Oct; 56(4):335-43. PubMed ID: 17889553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. KR-62980: a novel peroxisome proliferator-activated receptor gamma agonist with weak adipogenic effects.
    Kim KR; Lee JH; Kim SJ; Rhee SD; Jung WH; Yang SD; Kim SS; Ahn JH; Cheon HG
    Biochem Pharmacol; 2006 Aug; 72(4):446-54. PubMed ID: 16797489
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LT175 is a novel PPARα/γ ligand with potent insulin-sensitizing effects and reduced adipogenic properties.
    Gilardi F; Giudici M; Mitro N; Maschi O; Guerrini U; Rando G; Maggi A; Cermenati G; Laghezza A; Loiodice F; Pochetti G; Lavecchia A; Caruso D; De Fabiani E; Bamberg K; Crestani M
    J Biol Chem; 2014 Mar; 289(10):6908-6920. PubMed ID: 24451380
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distinct properties and advantages of a novel peroxisome proliferator-activated protein [gamma] selective modulator.
    Berger JP; Petro AE; Macnaul KL; Kelly LJ; Zhang BB; Richards K; Elbrecht A; Johnson BA; Zhou G; Doebber TW; Biswas C; Parikh M; Sharma N; Tanen MR; Thompson GM; Ventre J; Adams AD; Mosley R; Surwit RS; Moller DE
    Mol Endocrinol; 2003 Apr; 17(4):662-76. PubMed ID: 12554792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.